tirzepatide and cyanocobalamin Troubling Findings in Study of GLP-1 Compounders Tirzepatide Programs

Tirzepatide (brand Mounjaro), a dual GIP/GLP-1 agonist, was approved for diabetes (2022) and for weight loss as Zepbound (2023)

The interaction between microglia and astrocytes, particularly the activation of neuroprotective A2 astrocytes, could further contribute to mitigating neuroinflammation and restoring neural homeostasis

However, genetic predisposition does not predict exact medication responseindividual response varies widely

As the body burns stored fat, some individuals may notice changes in areas where fat is commonly stored, including the abdomen

Rouru, J., Isaksson, K., Santti, E., Huupponen, R

If symptoms appear after every dose and dont improve over time